Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin for cognitive impairment in schizophrenia
CTR20210675Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Started Apr 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20210675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210675.